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Serum Neopterin Level Predicts HIV-Related
Mortality but Not Progression to AIDS
or Development of Neurological Disease
in Gay Men and Parenteral Drug Users
Ned Sacktor, MD; Xinhua Liu, PhD; Matei Popescu, MD; Karen Marder, MD, MPH;
Yaakov Stern, PhD; Richard Mayeux, MD, MSE
Objective: To investigate the ability of elevated serum
neopterin levels to predict independently mortality, pro-
gression to acquired immunodeficiency syndrome, and
development of neurological disease.
Design: Cross-sectional and longitudinal study of gay
and/or bisexual men and parenteral drug users.
Setting and Patients: Patients included human im-
munodeficiency virus (HIV)\p=m-\negativeand \p=m-\positivegay
and/or bisexual men and parenteral drug\p=m-\usingmen and
women who volunteered for an outpatient study of the
natural history of HIV infection.
Results: Serum neopterin levels were significantly el-
evated in HIV-positive patients (mean, 18.0 nmol/L; SD,
19.2 nmol/L), compared with those in HIV-negative pa-
tients (mean, 7.5 nmol/L; SD, 5.5 nmol/L) (P<.001). No
differences in the serum neopterin levels could be de-
tected between gay men and parenteral drug users. In HIV\x=req-\
positive patients, women had a higher serum neopterin level
than did men (P=.03). The elevated serum neopterin lev-
els were associated with an advanced clinical stage of HIV
infection. After adjusting for the CD4 lymphocyte count
and other potential confounders, the serum neopterin level
was a significant independent predictor of mortality. The
elevated serum neopterin levels did not predict progres-
sion to acquired immunodeficiency syndrome or develop-
ment of clinically significant neurological disease.
Conclusion: An elevated serum neopterin level pre-
dicts mortality, but it does not predict progression to ac-
quired immunodeficiency syndrome or development of
neurological disease among HIV-infected individuals.
(Arch Neurol. 1995;52:676-679)
Neopterin, derived fromguanosine triphos-phate, is an intermedi¬ate product in thesynthesis of tetrahydro-
biopterin, which is an essential cofactor for
tyrosine and tryptophan hydroxylation.1
Neopterin is produced by monocytes and
macrophages during immune activation,
and the level of serum neopterin is el¬
evated in viral and bacterial infections, in
cancer, and during allograft rejection.2
Macrophages and microglia are principal
cell types that support productive hu¬
man immunodeficiency virus (HIV) in¬
fection,3·4 and products of these cells, such
as neopterin, may be an indicator of neu¬
rological disease.5
Elevated serum neopterin levels are
potential prognostic markers in HIV in¬
fection for mortality1·6 and progression to
acquired immunodeficiency syndrome(AIDS).1·2·7"10 However, the ability of se¬
rum neopterin levels to predict the prog¬
nosis independent of potential confound¬
ers, such as the CD4 lymphocyte count,
is in doubt.11 To our knowledge, the abil¬
ity of serum neopterin levels to predict the
development of HIV-related neurological
disease has not been evaluated previ¬
ously. This study assessed the value of the
serum neopterin level as an independent
prognostic indicator for mortality, the tran¬
sition to AIDS, and the development of
HIV-related neurological disease in both
gay men and parenteral drug users.
RESULTS
Serum neopterin levels were measured in
140 gay and/or bisexual men and in 129
men and women who were drug users at
baseline (Table 1 ). Elevated serum neop¬
terin levels were significantly associated
with the HIV serostatus (HIV-positive pa-
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METHODS
Patients included HIV-negative and -positive gay and/or bi¬
sexual men and parenteral drug users of both sexes who
volunteered for a study of the natural history of HIV in¬
fection. Patients were recruited via word of mouth at an
infectious disease clinic and at a methadone maintenance
clinic and via two announcements that were made in gay
monthly newsletters and one announcement that was made
in a newspaper. Inclusion and exclusion criteria and semi¬
annual standardized medical, neurological, and neuropsy¬
chological evaluations have been described elsewhere.12"14
Blood tests included HIV serology that was per¬
formed by using an enzyme-linked immunosorbent assay
and confirmed by Western blot, T-cell subset counts with
a fluorescent cell sorter (EPIC-C, Coulter Corp, Hialeah,
Fia), a p24 antigen assay with a standard kit (DuPont, Wil¬
mington, Del), and an acid-labile interferon alfa titer(method available on request). The serum neopterin level
was determined from plasma specimens that were frozen
for storage at
—
70°C by using a radioimmunoassay kit(Neopterin 1 RIA Kit, manufactured by IBL, Germany, for
INCSTAR Corp, Stillwater, Minn).
In a cross-sectional study, we investigated the rela¬
tionship between serum neopterin levels and clinical and
laboratory characteristics that were assessed at each pa¬
tient's first examination. In a longitudinal study, we ana¬
lyzed the capacity of the baseline serum neopterin level to
predict the following outcomes: mortality; progression to
AIDS as defined by the 1987 criteria of the Centers for Dis¬
ease Control and Prevention, Atlanta, Ga'3; and develop¬
ment of neurological disease. All patients who died dur¬
ing the 3V2-year period of follow-up were included in the
analysis. The date on which AIDS developed was assumed
to have occurred at the midpoint between the prior evalu¬
ation and the first follow-up visit when AIDS was present,
or at the midpoint between the prior evaluation and death.
A summary score to reflect the overall degree of neurologi¬
cal disability was calculated based on a modified version
of the Kurtzke Disability Status Scale for Multiple Sclero¬
sis (ie, Kurtzke score).1416 Meaningful neurological dis¬
ease was considered present if the Kurtzke score wors¬
ened from 0 to 2 (no or minimal disability) at baseline, to
3 (moderate disability although fully ambulatory) or greater
during follow-up. Findings from the neuropsychological
testing were defined as abnormal based on the neuropsy-
chologists' clinical impression of the full battery of tests,
as described previously.14
Wilcoxon's rank sum test was used to assess differ¬
ences in serum neopterin levels between the two different
subgroups, eg, HIV-positive and HIV-negative patients. To
assess differences among the three different subgroups, the
Kruskal-Wallis test was performed. The level of serum neop¬
terin was dichotomized into groups with a high and low
level of serum neopterin, by using the median in all HIV-
positive patients. Comparisons of variables of interest in
the two groups (those patients with high and low levels of
serum neopterin) were performed either by using Wilcox¬
on's rank sum test for continuous variables with a skewed
distribution17 or the
 2 test with Yates' Correction for Con¬
tinuity for categorical variables.18 Variables that were shown
to be significantly associated with the serum neopterin level
at baseline or clinically significant variables (eg, age) were
investigated further, by using logistic regression.19 Con¬
tinuous variables were converted to binary forms with
cutoff points that corresponded to the median of the HIV-
positive population, except for the CD4 lymphocyte count,
for which a cutoff value of 0.20X107L (200/µ ) was
chosen because of the AIDS-defining significance of this
cutoff value. The risk ratios for death, AIDS, or neurologi¬
cal disability for the level of serum neopterin were calcu¬
lated by using Cox proportional hazards models.20 The mor¬
tality risk ratio was adjusted for variables that were
independent predictors of mortality and were significant
in predicting high serum neopterin levels at baseline.
tients [mean, 18.0 nmol/L; SD, 19.2 nmol/L] vs HIV-
negative patients [mean, 7.5 nmol/L; SD, 5.5 nmol/L];
P<.001). Serum neopterin levels did not differ by risk
group (gay men vs parenteral drug users) among HIV-
negative or -positive patients. Serum neopterin levels did
not differ by gender among HIV-negative patients. Among
HIV-positive patients, women had a significantly higher
serum neopterin level than did men (mean, 22.5 vs 17.5
nmol/L; P=.03). After adjustment for gender, age, and risk
group by using logistic regression, the odds ratio (OR)
for HIV seropositivity associated with high serum neop¬
terin levels (above the median in HIV-positive patients,
12.2 nmol/L) was 9.6 (95% confidence interval [CI], 4.5
to 20.7). High serum neopterin levels were associated with
advanced clinical stages (ie, AIDS or AIDS-related com¬
plex, compared with those in less symptomatic HIV-
positive patients21; however, high serum neopterin lev¬
els were inversely related to a mean CD4 lymphocyte
count and hemoglobin level (Table 2). After adjusting
for the effect of the CD4 lymphocyte count and hemo¬
globin level, the OR for an advanced clinical stage of HIV
infection (ie, AIDS or AIDS-related complex) associated
with a high serum neopterin level was 2.2 (95% CI, 1.1
to 4.5).
Forty-six deaths (all related to HIV) occurred be¬
tween the baseline visit and the end of the study among
176 HIV-positive patients. Thirty-six deaths occurred
among the 89 patients with high serum neopterin levels
at baseline, and 10 deaths occurred among the 87 pa¬
tients with low serum neopterin levels. Cox propor¬
tional hazards models were used to assess the mortality
risk that was associated with the serum neopterin level.
The unadjusted mortality risk ratio that was associated
with high serum neopterin levels was 5.5 (95% CI, 2.6
to 11.9). The CD4 lymphocyte count (<0.20X 107L), he¬
moglobin level (s 134.5 g/L g/dL), interferon alfa titer(>1:4), and advanced clinical stage (AIDS or AIDS-
related complex) were all predictors of mortality and were
also associated with high serum neopterin levels at base¬
line. After adjusting for these four variables, the CD4 lym¬
phocyte count (risk ratio, 6.4; 95% CI, 2.9 to 14.0;
P<.001) and high serum neopterin levels (risk ratio, 2.4;
95% CI, 1.1 to 5.7; P=.04) were still significant predic¬
tors of mortality. In other words, an HIV-positive pa-
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Table 1. Serum Neopterin Levels in HIV-Seronegative
and
-Seropositive Gay Men and PDUs by HIV Status,




Subgroups  Mean SD  
HIV status
All negatives 93 7.5 5.5
All positives 176 18.0 19.2 <.001
Risk group
HIV-/gay men 43 8.0 6.1
HIV-/PDU men 31 6.0 2.8
HIV-/PDU women 19 8.4 6.4 .211
Gender
HIV+/gaymen 97 19.2 22.8
HIV+/PDU men 48 14.2 12.9
HIV+/PDU women 31 22.1 24.0 .046
*HIV indicates human immunodeficiency virus; PDUs, parenteral drug
users; minus sign, seronegative; PDU, parenteral drug-using; and plus
sign, seropositive.
tient with a CD4 count of 0.20X 107L or less was six times
more likely to die during the next 3Vi years than a pa¬
tient with a CD4 count of greater than 0.20 X109/L, and
a patient with a CD4 count of 0.20X 109/L or less and a
high serum neopterin level was 15 times more likely to
die than a patient with a CD4 count of greater than
0.20X 109/L and a low serum neopterin level. After ad¬
justing for the CD4 lymphocyte count and the serum
neopterin level, hemoglobin and interferon alfa values
and an advanced clinical stage were no longer predic¬
tors of mortality. There was no significant interaction of
the serum neopterin level and CD4 lymphocyte count in
predicting mortality (P>.10).
Seventeen of 30 patients whose conditions pro¬
gressed to AIDS during the study period had a baseline
serum neopterin level greater than 12.2 nmol/L, and 13
had baseline serum neopterin levels below this value. The
risk ratio for progression to AIDS in patients with high
serum neopterin levels when compared with that in per¬
sons with low serum neopterin levels at baseline was not
significant (ie, risk ratio, 1.5; 95% CI, 0.7 to 3.1).
Twenty-seven of 75 patients experienced signifi¬
cant neurological disease in the group with high serum
neopterin levels, compared with 24 of 78 patients in the
group with low serum neopterin levels. The risk ratio for
development of significant neurological disease in pa¬
tients with high serum neopterin levels, compared with
that for patients with low serum neopterin levels at base¬
line, was not significant (ie, risk ratio, 1.4; 95% CI, 0.8
to 2.5).
COMMENT
In this study, elevated serum neopterin levels were in¬
dependently associated with an advanced clinical stage
at baseline and were inversely related to a mean CD4 lym¬
phocyte count and hemoglobin level. Serum neopterin
levels were significantly higher in HIV-positive than in
HIV-negative patients, but no difference in serum neop¬
terin levels were found among gay men and parenteral
Table 2. Comparison of Demographic and Clinical
Characteristics in HIV-Seropositive Gay Men and PDUs
With High vs Low Serum Neopterin Levels at Baseline Visit*
Serum Neopterin Level, nmol/L
_
>12.2 (n=89) <12.2 (n=87)  
Age, y
Mean (SD) 39.3(7.12) 38.4(8.36) .402
Sex, %
F 20.2 14.9
M 79.8 85.1 .470
Risk group, %
Gay men 55.1 55.2
PDUs 44.9 44.8 1.000
Clinical stage, %
AIDS 8.0 3.7 .333
AIDS or ARC 72.7 43.2 <.001
CD4 lymphocyte count
Mean (SD), x109/L 0.29(0.23) 0.44(0.22) <.001
£0.20 X107L, % 42.5 14.1 <.001
Hemoglobin level
Mean (SD), g/L 127(15.9) 139(13.7) -c.001
==134.5 g/L, % 65.9 33.3 <.001
Interferon alfa titer
(>1:4), % 47.5 26.3 .010
p24 antigenemia
(>9), % 21.3 13.0 .246
Kurtzke score
(>3), % 16.5 11.1 .439
Abnormal
neuropsychological
testing results, % 40.2 29.6 .202
"HIV indicates human immunodeficiency virus; PDUs, parenteral drug
users; AIDS, acquired immunodeficiency syndrome; and ARC, AIDS-related
complex.
drug users. This finding fails to support the hypothesis
that the level of serum neopterin, an indicator of im¬
mune activation, might be elevated in drug users as a re¬
sult of continuous antigen exposure. Among HIV-
positive patients, women had higher serum neopterin
levels than did men. Further investigation to evaluate gen¬
der differences in elevated serum neopterin levels is war¬
ranted.
The results of this study confirm those of other stud¬
ies,1·6 suggesting that elevated serum neopterin levels pre¬
dict mortality. After adjusting for potential confounders(CD4 lymphocyte count, hemoglobin and interferon alfa
levels, and advanced clinical stage), high serum neop¬
terin levels remained a significant predictor of mor¬
tality.
However, high serum neopterin levels did not pre¬
dict the development of neurological disease. In con¬
trast to the findings in other studies,1·2·7"10 we found that
the serum neopterin level was not a predictor of progres¬
sion to AIDS. The small number of patients in whom AIDS
developed in our study could account for the discrep¬
ancy between our results and those of previous studies.
In addition, patients who did not return for follow-up
visits were interviewed by telephone to obtain further data
on mortality only.
The present analysis was based on data from a preva¬
lence sample of HIV-infected patients who were fol¬
lowed up longitudinally and whose duration of infec-
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tion, an important prognostic factor,7·22,23 was not known.
It is possible that the predictive value of serum neop¬
terin levels changes during the course of HIV infection.7
This could possibly explain the discrepancy between our
results and those of previous studies concerning the in¬
dependent predictive value of the serum neopterin level.
An elevated serum neopterin level is associated with
an advanced clinical stage (AIDS or AIDS-related com¬
plex) at baseline, and it predicts mortality after adjust¬
ing for the CD4 lymphocyte count and other potential
confounders. In our study, elevated serum neopterin lev¬
els did not predict progression to AIDS or development
of neurological disease.
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